President Donald Trump’s physician, Dr. Sean P. Barbabella, announced that after conducting a battery of tests, he found that ...

Moderna ends its CMV vaccine program after a Phase 3 trial failed to meet efficacy goals, but maintains its 2028 breakeven ...

Moderna stock toppled Thursday after the biotech company's experimental CMV vaccine failed in a Phase 3 study of 7,500 women.

Moderna said its cytomegalovirus (CMV) vaccine, mRNA-1647, failed to prevent infection in women of childbearing age in a ...

The vaccine, known as mRNA-1647, showed disappointing efficacy against primary CMV infection in healthy women, ranging from ...

(NASDAQ:MRNA) today announced topline results from a Phase 3 pivotal trial evaluating the efficacy of mRNA-1647, the ...

Covid vaccines may come with a tantalizing benefit that has nothing to do with the virus they’re designed to protect against: boosting the immune system to better fight tumors during cancer treatment.

Since 1965, messenger RNA (mRNA) vaccines have been studied for cancer treatment, but it was the technological advances in vaccines during the COVID pandemic that helped accelerate research. Currently ...

An mRNA vaccine developed by researchers from Japan suppressed abnormal blood vessel growth or neovascularization in the retina of mouse models. Neovascularization is a condition that is caused by age ...

CHONGQING, CHINA - JULY 29: In this photo illustration, a smartphone displays the logo of Moderna Inc. (NASDAQ: MRNA), a biotechnology company known for its mRNA-based vaccines and therapeutics, in ...

Singling out Health Secretary Robert F. Kennedy Jr.’s worst decision is difficult, because the competition is fierce, but near the top of the list was his decision to terminate a series of federal ...